SuperworthBIO-TECHNE profit margin TECH
Gross, operating and net profit as a share of revenue over the last twelve months, from 2010.
- Net margin, 12 months
- 15.0%
- Operating margin, 12 months
- 20.7%
- Net margin on a year earlier
- +8.9 pts
- Peer median
- 26.3%
Over the twelve months to Jun 30, 2026, BIO-TECHNE kept 15.0% of its revenue as net profit, with an operating margin of 20.7% and a gross margin of 65.8%.
Five years earlier its net margin was 15.1%.
The median for 10 biotech stocks of a similar size is 26.3%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2026 | 15.0% | 20.7% | 65.8% |
| FY2025 | 6.0% | 8.4% | 64.8% |
| FY2024 | 14.5% | 17.8% | 66.4% |
| FY2023 | 25.1% | 26.3% | 67.7% |
| FY2022 | 24.6% | 26.8% | 68.4% |
| FY2021 | 15.1% | 25.5% | 68.0% |
| FY2020 | 31.0% | 21.3% | 65.4% |
| FY2019 | 13.5% | 20.5% | 66.3% |
| FY2018 | 19.6% | 21.2% | 67.2% |
| FY2017 | 13.5% | 21.4% | 66.5% |
| FY2016 | 20.9% | 30.2% | 67.5% |
| FY2015 | 23.8% | 0.0% | 67.9% |
| FY2014 | 31.0% | 44.7% | 70.3% |
| FY2013 | 36.2% | 51.0% | 74.4% |
| FY2012 | 35.7% | 52.8% | 75.0% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q4 FY26 | 15.0% | +8.9 pts | 20.7% | |
| Q3 FY26 | 9.0% | −1.8 pts | 12.7% | |
| Q2 FY26 | 6.7% | −6.5 pts | 9.6% | |
| Q1 FY26 | 6.4% | −6.5 pts | 9.0% | |
| Q4 FY25 | 6.0% | −8.5 pts | 8.4% | |
| Q3 FY25 | 10.9% | −6.7 pts | 14.2% | |
| Q2 FY25 | 13.2% | −6.4 pts | 16.7% | |
| Q1 FY25 | 12.9% | −8.7 pts | 16.3% | |
| Q4 FY24 | 14.5% | −10.6 pts | 17.8% | |
| Q3 FY24 | 17.6% | −6.6 pts | 22.1% | |
| Q2 FY24 | 19.6% | −3.8 pts | 23.5% | |
| Q1 FY24 | 21.6% | −4.6 pts | 26.1% |
Against its peers
Companies in Biotechnology nearest BIO-TECHNE's size, closest first, today.
| Company | Profit margin |
|---|---|
| TECHBIO-TECHNE | 15.0% |
| RGENRepligen | 5.3% |
| KRYSKrystal Biotech | 54.8% |
| HALOHalozyme Therapeutics | 24.9% |
| NBIXNeurocrine Biosciences | 20.9% |
| EXELExelixis | 35.3% |
| INCYIncyte | 27.7% |
| UTHRUnited Therapeutics | 41.6% |
| ALNYAlnylam Pharmaceuticals | 16.8% |
| ONCBeOne Medicines | 10.7% |
| ADMAAdma Biologics | 33.0% |
| Peer median | 26.3% |
Where BIO-TECHNE ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on BIO-TECHNE
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.